hVIVO Appoints Shaun Chilton as Non-Executive Chair

Open Orphan Plc ( (GB:HVO) ) has provided an update.

hVIVO plc has announced the proposed appointment of Shaun Chilton as Non-Executive Chair, pending customary due diligence. Chilton brings over 30 years of experience in leading both private and public businesses, with a strong track record in sales growth and enterprise value. His appointment is expected to enhance hVIVO’s board with his extensive sector-relevant expertise, potentially impacting the company’s strategic direction and market positioning.

The most recent analyst rating on (GB:HVO) stock is a Buy with a £35.00 price target. To see the full list of analyst forecasts on Open Orphan Plc stock, see the GB:HVO Stock Forecast page.

Spark’s Take on GB:HVO Stock

According to Spark, TipRanks’ AI Analyst, GB:HVO is a Outperform.

Open Orphan Plc’s strong financial performance and positive corporate events drive its favorable stock score. However, technical analysis indicates bearish trends, which could pose a short-term risk. The stock’s low valuation and high dividend yield present a compelling investment opportunity.

To see Spark’s full report on GB:HVO stock, click here.

More about Open Orphan Plc

hVIVO plc is a full-service Contract Research Organisation (CRO) and a global leader in human challenge trials. The company provides comprehensive clinical development services to a diverse client base, including major biopharma companies. hVIVO specializes in human challenge trials for infectious and respiratory diseases, utilizing a state-of-the-art quarantine facility in London. The company also offers virology and immunology laboratory services under the hLAB brand and operates through subsidiaries CRS and Venn Life Sciences, providing early-phase clinical trial services and drug development consulting.

Average Trading Volume: 3,436,139

Technical Sentiment Signal: Sell

Current Market Cap: £68.7M

Find detailed analytics on HVO stock on TipRanks’ Stock Analysis page.